Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.53 |
| ▸ | CES1 | P23141 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29127613 | 1.00 | CES2 (0.53) | CES2CES1DRD2NPC1RAB9A | |
| SCHEMBL29406527 | 1.00 | CES2 (0.53) | CES2CES1DRD2NPC1RAB9A | |
| SCHEMBL9827785 | 0.86 | CES2 (0.53) | CES2CES1DRD2NPC1RAB9A | |
| SCHEMBL9115881 | 0.85 | NPC1 (0.46) | CES2CES1DRD2NPC1RAB9A | |
| SCHEMBL13588197 | 0.84 | CES2 (0.55) | CES2CES1DRD2NPC1RAB9A | |
| SCHEMBL28289421 | 0.84 | CES2 (0.55) | CES2CES1DRD2NPC1RAB9A | |
| Ethylene SCHEMBL10996445 | 0.83 | CES2 (0.50) | CES2CES1DRD2NPC1RAB9A | |
| SCHEMBL5636039 | 0.83 | KEAP1 (0.54) | CES2CES1DRD2NPC1RAB9A | |
| SCHEMBL5078142 | 0.83 | CES2 (0.53) | CES2CES1DRD2NPC1RAB9A | |
| SCHEMBL31661689 | 0.83 | CES2 (0.53) | CES2CES1DRD2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118109434-A | Transaminase and its application in synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-118006577-A | Transaminase and application thereof in synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117965480-A | Recombinant aminotransferase and application thereof in synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-114075557-B | Recombinant aminotransferase and its use in the synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-114075557-A | Recombinant transaminase and application thereof in synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2022-02-22 | — | — | CN | claimed |
| EP-4420732-A2 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2024-08-28 | — | — | EP | disclosed |
| CN-118109434-A | Transaminase and its application in synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118109434-A | Transaminase and its application in synthesizing (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118006577-A | Transaminase and application thereof in synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-118006577-A | Transaminase and application thereof in synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117965480-A | Recombinant aminotransferase and application thereof in synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117965480-A | Recombinant aminotransferase and application thereof in synthesis of (R) -2- (2, 5-difluorophenyl) pyrrolidine | 上海飞腾医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20150005280-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-01-01 | — | — | US | disclosed |
| US-20150005280-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-01-01 | — | — | US | disclosed |
| US-20150005280-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-01-01 | — | — | US | disclosed |
| US-20140371217-A1 | SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-12-18 | — | — | US | disclosed |
| US-20140371217-A1 | SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-12-18 | — | — | US | disclosed |
| US-20140371217-A1 | SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-12-18 | — | — | US | disclosed |
| WO-2013088256-A1 | SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013088257-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005280-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | NTRK1, MUSK, NTRK3 | CES2 4174/4885CES1 4168/4885DRD2 4737/4885 |
| US-20140371217-A1 | SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS | MUSK, DMPK, PNCK | CES2 4541/4885CES1 3236/4885DRD2 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.